Does the media favor FBIO or PALI?

In the previous week, Palisade Bio had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 2 mentions for Palisade Bio and 1 mentions for Fortress Biotech. Palisade Bio's average media sentiment score of 1.19 beat Fortress Biotech's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer FBIO or IKT?

In the previous week, Inhibikase Therapeutics had 3 more articles in the media than Fortress Biotech. MarketBeat recorded 4 mentions for Inhibikase Therapeutics and 1 mentions for Fortress Biotech. Inhibikase Therapeutics' average media sentiment score of 0.71 beat Fortress Biotech's score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibikase Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VNDA or FBIO?

In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for Vanda Pharmaceuticals and 1 mentions for Fortress Biotech. Vanda Pharmaceuticals' average media sentiment score of 1.27 beat Fortress Biotech's score of 0.00 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AMRN or FBIO?

In the previous week, Amarin had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for Amarin and 1 mentions for Fortress Biotech. Amarin's average media sentiment score of 0.74 beat Fortress Biotech's score of 0.00 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to FBIO or TTRX?

In the previous week, Fortress Biotech and Fortress Biotech both had 1 articles in the media. Fortress Biotech's average media sentiment score of 0.00 beat Turn Therapeutics' score of -0.21 indicating that Fortress Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Fortress Biotech (FBIO) Competitors

$2.72 +0.01 (+0.37%)

As of 09/4/2026 04:00 PM Eastern

Compare

FBIO vs. PALI, IKT, VNDA, AMRN, and TTRX

Should you buy Fortress Biotech stock or one of its competitors? Fortress Biotech's main competitors and comparable companies include Palisade Bio (PALI), Inhibikase Therapeutics (IKT), Vanda Pharmaceuticals (VNDA), Amarin (AMRN), and Turn Therapeutics (TTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Fortress Biotech compare to Palisade Bio?

Fortress Biotech (NASDAQ:FBIO) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Fortress Biotech has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.43	$6.82M	$2.64	1.03
Palisade Bio	$250K	1,456.90	-$16.78M	-$0.48	N/A

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Comparatively, 0.1% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Fortress Biotech presently has a consensus target price of $17.00, indicating a potential upside of 525.00%. Palisade Bio has a consensus target price of $9.00, indicating a potential upside of 330.62%. Given Fortress Biotech's higher probable upside, equities research analysts plainly believe Fortress Biotech is more favorable than Palisade Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Palisade Bio had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 2 mentions for Palisade Bio and 1 mentions for Fortress Biotech. Palisade Bio's average media sentiment score of 1.19 beat Fortress Biotech's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortress Biotech has a net margin of 163.32% compared to Palisade Bio's net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Palisade Bio	N/A	-33.47%	-31.79%

Fortress Biotech has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market.

Summary

Fortress Biotech beats Palisade Bio on 10 of the 17 factors compared between the two stocks.

How does Fortress Biotech compare to Inhibikase Therapeutics?

Fortress Biotech (NASDAQ:FBIO) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Fortress Biotech has a net margin of 163.32% compared to Inhibikase Therapeutics' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Fortress Biotech has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Fortress Biotech presently has a consensus price target of $17.00, suggesting a potential upside of 525.00%. Inhibikase Therapeutics has a consensus price target of $5.40, suggesting a potential upside of 116.00%. Given Fortress Biotech's higher possible upside, equities research analysts clearly believe Fortress Biotech is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Fortress Biotech has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.43	$6.82M	$2.64	1.03
Inhibikase Therapeutics	$260K	1,341.73	-$48.26M	-$0.43	N/A

In the previous week, Inhibikase Therapeutics had 3 more articles in the media than Fortress Biotech. MarketBeat recorded 4 mentions for Inhibikase Therapeutics and 1 mentions for Fortress Biotech. Inhibikase Therapeutics' average media sentiment score of 0.71 beat Fortress Biotech's score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibikase Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Fortress Biotech beats Inhibikase Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for Vanda Pharmaceuticals and 1 mentions for Fortress Biotech. Vanda Pharmaceuticals' average media sentiment score of 1.27 beat Fortress Biotech's score of 0.00 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vanda Pharmaceuticals currently has a consensus target price of $13.70, suggesting a potential upside of 152.30%. Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 525.00%. Given Fortress Biotech's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 28.5% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Vanda Pharmaceuticals has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Fortress Biotech has a net margin of 163.32% compared to Vanda Pharmaceuticals' net margin of -127.41%. Fortress Biotech's return on equity of 83.47% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Fortress Biotech	163.32%	83.47%	42.98%

Fortress Biotech has lower revenue, but higher earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.52	-$220.47M	-$4.63	N/A
Fortress Biotech	$63.26M	1.43	$6.82M	$2.64	1.03

Summary

Fortress Biotech beats Vanda Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to Amarin?

Amarin (NASDAQ:AMRN) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Fortress Biotech has a net margin of 163.32% compared to Amarin's net margin of -14.56%. Fortress Biotech's return on equity of 83.47% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Fortress Biotech	163.32%	83.47%	42.98%

Amarin has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

22.3% of Amarin shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 28.5% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Fortress Biotech has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.35	-$38.80M	-$0.99	N/A
Fortress Biotech	$63.26M	1.43	$6.82M	$2.64	1.03

Amarin presently has a consensus target price of $13.00, suggesting a potential downside of 4.62%. Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 525.00%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Fortress Biotech is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Amarin had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for Amarin and 1 mentions for Fortress Biotech. Amarin's average media sentiment score of 0.74 beat Fortress Biotech's score of 0.00 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fortress Biotech beats Amarin on 13 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to Turn Therapeutics?

Fortress Biotech (NASDAQ:FBIO) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

96.5% of Fortress Biotech shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Fortress Biotech has a net margin of 163.32% compared to Turn Therapeutics' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Turn Therapeutics	N/A	-230.84%	-53.19%

In the previous week, Fortress Biotech and Fortress Biotech both had 1 articles in the media. Fortress Biotech's average media sentiment score of 0.00 beat Turn Therapeutics' score of -0.21 indicating that Fortress Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fortress Biotech presently has a consensus price target of $17.00, indicating a potential upside of 525.00%. Turn Therapeutics has a consensus price target of $8.00, indicating a potential downside of 18.37%. Given Fortress Biotech's higher probable upside, research analysts clearly believe Fortress Biotech is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Fortress Biotech has higher revenue and earnings than Turn Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.43	$6.82M	$2.64	1.03
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

Summary

Fortress Biotech beats Turn Therapeutics on 12 of the 14 factors compared between the two stocks.

Get Fortress Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBIO vs. The Competition

Export

Metric	Fortress Biotech	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$90.71M	$12.25B	$7.25B	$12.91B
Dividend Yield	N/A	2.58%	2.53%	9.14%
P/E Ratio	1.03	792.20	273.82	25.45
Price / Sales	1.43	758.94	634.83	106.58
Price / Cash	N/A	90.26	77.08	52.44
Price / Book	0.44	12.47	12.85	6.17
Net Income	$6.82M	$2.83B	$3.49B	$350.08M
7 Day Performance	-1.81%	4.03%	1.04%	-0.14%
1 Month Performance	-1.81%	5.80%	5.39%	0.94%
1 Year Performance	-26.68%	10.00%	24.18%	14.02%

Fortress Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBIO Fortress Biotech	2.2474 of 5 stars	$2.72 +0.4%	$17.00 +525.0%	-26.7%	$90.71M	$63.26M	1.03	170
PALI Palisade Bio	2.7094 of 5 stars	$1.95 -2.5%	$9.00 +361.5%	+233.6%	$348.54M	$250K	N/A	10	Positive News
IKT Inhibikase Therapeutics	1.9587 of 5 stars	$2.31 -4.1%	$5.40 +133.8%	+49.7%	$336.28M	$260K	N/A	6	News Coverage
VNDA Vanda Pharmaceuticals	2.5433 of 5 stars	$5.40 +2.1%	$13.70 +153.7%	+17.8%	$319.85M	$216.10M	N/A	290	Positive News
AMRN Amarin	0.8928 of 5 stars	$13.88 -0.6%	$13.00 -6.3%	-11.1%	$295.09M	$213.65M	N/A	360

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBIO) was last updated on 9/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fortress Biotech (FBIO) Competitors

FBIO vs. PALI, IKT, VNDA, AMRN, and TTRX

How does Fortress Biotech compare to Palisade Bio?

Summary

How does Fortress Biotech compare to Inhibikase Therapeutics?

Summary

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Summary

How does Fortress Biotech compare to Amarin?

Summary

How does Fortress Biotech compare to Turn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fortress Biotech (FBIO) Competitors

FBIO vs. PALI, IKT, VNDA, AMRN, and TTRX

How does Fortress Biotech compare to Palisade Bio?

Which has preferable valuation and earnings, FBIO or PALI?

Do insiders & institutionals believe in FBIO or PALI?

Do analysts recommend FBIO or PALI?

Does the media favor FBIO or PALI?

Is FBIO or PALI more profitable?

Which has more volatility and risk, FBIO or PALI?

Summary

How does Fortress Biotech compare to Inhibikase Therapeutics?

Is FBIO or IKT more profitable?

Do insiders & institutionals hold more shares of FBIO or IKT?

Which has more volatility & risk, FBIO or IKT?

Do analysts rate FBIO or IKT?

Which has preferable valuation & earnings, FBIO or IKT?

Does the media prefer FBIO or IKT?

Summary

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Does the media refer more to VNDA or FBIO?

Do analysts prefer VNDA or FBIO?

Do insiders & institutionals have more ownership in VNDA or FBIO?

Which has more risk and volatility, VNDA or FBIO?

Is VNDA or FBIO more profitable?

Which has preferable earnings & valuation, VNDA or FBIO?

Summary

How does Fortress Biotech compare to Amarin?

Is AMRN or FBIO more profitable?

Which has more risk & volatility, AMRN or FBIO?

Do insiders and institutionals hold more shares of AMRN or FBIO?

Which has better earnings and valuation, AMRN or FBIO?

Do analysts prefer AMRN or FBIO?

Does the media favor AMRN or FBIO?

Summary

How does Fortress Biotech compare to Turn Therapeutics?

Do institutionals and insiders hold more shares of FBIO or TTRX?

Is FBIO or TTRX more profitable?

Does the media refer more to FBIO or TTRX?

Do analysts rate FBIO or TTRX?

Which has better earnings and valuation, FBIO or TTRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools